Compare BLDP & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLDP | PRCT |
|---|---|---|
| Founded | 1979 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2009 | 2021 |
| Metric | BLDP | PRCT |
|---|---|---|
| Price | $3.51 | $20.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $2.34 | ★ $35.44 |
| AVG Volume (30 Days) | ★ 7.5M | 1.7M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | $14.53 | $31.34 |
| Revenue Next Year | $18.02 | $24.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $1.65 | $19.35 |
| 52 Week High | $6.57 | $62.17 |
| Indicator | BLDP | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 35.02 | 37.76 |
| Support Level | $2.55 | $20.18 |
| Resistance Level | $3.71 | $29.27 |
| Average True Range (ATR) | 0.36 | 1.70 |
| MACD | -0.09 | -0.07 |
| Stochastic Oscillator | 1.33 | 13.67 |
Ballard Power Systems Inc is engaged in design, development, manufacture, sale and service of proton exchange membrane ("PEM") fuel cell products for a variety of applications, focusing on power products for bus, truck, rail, marine, stationary and emerging market (material handling, off-road and other) applications, as well as the delivery of services, including technology solutions, after sales services and training. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. Key geographical revenue is derived from United States followed by Poland, Canada, and other countries.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.